⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963871 | 0.74 | CDK2 (0.34) | — | |
| SCHEMBL9004255 | 0.74 | CDK2 (0.35) | — | |
| SCHEMBL5727005 | 0.74 | CDK2 (0.32) | — | |
| SCHEMBL21723351 | 0.65 | ALDH1A1 (0.34) | — | |
| SCHEMBL18857313 | 0.63 | CDK2 (0.32) | — | |
| SCHEMBL12263976 | 0.63 | CDK2 (0.32) | — | |
| SCHEMBL2619433 | 0.63 | PIK3CG (0.41) | — | |
| SCHEMBL2616422 | 0.63 | CDK2 (0.35) | — | |
| SCHEMBL20987794 | 0.61 | CDK2 (0.31) | — | |
| SCHEMBL5725556 | 0.61 | CDK2 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087951-B9 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1087951-B1 | CARBON SUBSTITUTED AMINOTHIAZOLE INHIBITORS OF CYCLIN DEPENDENT KINASES | BRISTOL MYERS SQUIBB CO (US) | 2005-02-09 | — | — | EP | disclosed |
| US-6720347-B2 | SUCH AS ETHYL-3-((E)-2-ACETAMIDO-THIAZOL-5-YL)-ACRYLATE FOR TREATMENT OF CANCER, PROLIFERATIVE DISEASES, INFLAMMATION, AND ARTHRITIS | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-13 | — | — | US | disclosed |
| US-20020165259-A1 | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases | RAWLINS DAVID B (US) | 2002-11-07 | — | — | US | disclosed |
| US-6407124-B1 | ANTICARCINOGENIC, ANTIPROLIFERATIVE, ANTIINFLAMMATORY, AND ANTIARTHRITIC AGENTS; ALZHEIMER*S DISEASE AND CARDIOVASCULAR DISORDER TREATMENT | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-18 | — | — | US | disclosed |